Plant Medicine · Mazatec · Teonanácatl · Research

Psilocybin Mushrooms — The Flesh of the Gods

teonanácatl · "divine mushroom" — used for over 10,000 years

A Mazatec healer named María Sabina had been guiding velada ceremonies in the mountains of Oaxaca for thirty years before a banker from New York arrived in 1955 and introduced her practice to the world — without her full understanding of the consequences. What followed was the psychedelic revolution, the war on drugs, and eventually some of the most rigorous clinical research into consciousness ever conducted. The mushroom itself had been there the whole time, doing what it had always done.

Before Wasson — The Long History

Humans have used psilocybin mushrooms for at least 10,000 years, with rock art from the Sahara (8,000–9,000 BCE) depicting mushroom-human figures, and Mesoamerican archaeological evidence showing consistent use across the Aztec, Mixtec, Zapotec and Mazatec cultures. The Aztec called them teonanácatl — "flesh of the gods" or "divine mushroom" — and used them in religious ceremonies, healing rituals and divination. When Spanish colonizers arrived in the sixteenth century, they identified the practice as demonic and attempted to suppress it, driving it underground where it survived intact in isolated communities like Huautla de Jiménez in Oaxaca's Sierra Mazateca — for four more centuries, entirely undisturbed by the outside world.

The Mazatec tradition that survived this suppression is a complete healing system. The chji nta:j ki ("wise person who knows") — usually translated as curandera or curandero — works with specific mushroom species (primarily Psilocybe mexicana, P. cubensis and related varieties) in the context of the velada: an all-night healing vigil conducted in near-total darkness, oriented toward diagnosis and healing of illness, location of lost people or objects, and communion with the divine. The mushrooms are not recreational; they are the diagnostic instrument of a sophisticated medical tradition.

Wasson, Life Magazine and the Price María Sabina Paid

On June 29, 1955, R. Gordon Wasson — a vice president of J.P. Morgan and amateur mycologist — arrived in Huautla de Jiménez with photographer Allan Richardson. To gain access to a velada, Wasson told María Sabina he was concerned about his son's whereabouts — a deception he later admitted publicly. Sabina, who had been performing veladas for over thirty years, conducted the ceremony. Wasson took spores back with him, which eventually reached Albert Hofmann in Switzerland, who isolated and synthesized psilocybin in 1958.

On May 13, 1957, Life magazine published Wasson's article "Seeking the Magic Mushroom" — the first account of psilocybin experience to reach a mass Western audience. Though he initially omitted Sabina's name, enough identifying detail remained that she was eventually identified. What followed destroyed her life as she had known it: Huautla de Jiménez was flooded with hippies, seekers and the merely curious; villagers, who blamed Sabina for defiling the velada's sacred purpose, burned her house down; she was briefly imprisoned; her son was murdered. She died in 1985, aged approximately ninety, having watched the sacred ceremony she had guarded become a tourist experience.

Sabina's own words: "Before Wasson, I felt that the saint children [mushrooms] elevated me. I don't feel that way anymore. The force has diminished. If Cayetano hadn't brought the foreigner... the saint children would have kept their power." This is not metaphorical. Sabina understood that the ceremonial container — the secrecy, the seriousness, the community accountability, the dieta — was part of what made the medicine work. Once the ceremony became a spectacle for curious outsiders, something essential was lost. The contemporary psychedelic scene, with its combination of genuine therapeutic intention and commercial tourism, is still negotiating this same tension.

The All-Night Healing Vigil

The Mazatec velada is a night-long ceremony typically conducted in complete darkness (the mushrooms heighten sensory sensitivity to the point where light becomes overwhelming) in the curandera's home. Participants — usually a small group, gathered around the one who is ill or seeking — ingest mushrooms together, with the curandera taking a higher dose than anyone else. The curandera then sings, prays and chants throughout the night — a mixture of Catholic prayers (the Mazatec tradition absorbed Christianity without replacing its own cosmology), indigenous invocations, and spontaneous guidance received from the mushroom spirits themselves.

The velada's purpose is consistently described as diagnostic and healing: the mushrooms allow the curandera to perceive the spiritual cause of illness, the location of what is lost, or the nature of what needs to change. Vomiting by participants — as in the ayahuasca tradition — is understood as the purging of illness rather than an unfortunate side effect. The ceremony ends at dawn; the subsequent period of rest and reflection is considered integral to the healing.

The Mushroom Species
Mazatec tradition distinguishes between multiple species with different characters and applications. Psilocybe mexicana (the original species Hofmann synthesized from) and P. cubensis are most commonly associated with velada use, but traditional knowledge distinguishes dozens of varieties, each with specific energetic qualities. The cultivated P. cubensis now used globally in therapeutic research and recreational contexts is one thread of a much more complex tradition.
The Chants — Words of Power
María Sabina's chants, recorded by ethnomycologist Henry Munn and published in 1973, are considered among the most extraordinary examples of oral literature ever documented — spontaneous poetry arising in the ceremony space, addressing the mushroom spirits, the sick person's body, the cosmos and God simultaneously. They have been set to music, translated into multiple languages and performed as poetry. Sabina herself distinguished between the chants she composed consciously and those she received from the mushrooms during ceremony: "I am a woman who shouts. I am a woman who whistles."

What Johns Hopkins and Imperial Have Found

The clinical research renaissance that began in the early 2000s — after three decades of prohibition-era suppression — has produced the most compelling therapeutic results in psychiatric research in a generation. The findings are consistent across multiple independent institutions and replicated across studies.

Mystical experience and therapeutic outcome: the most robust finding is counterintuitive — the degree to which a participant has a "complete mystical experience" (a sense of unity, sacredness, noetic quality, deeply felt positive mood, transcendence of time and space) predicts the therapeutic outcome months later. This finding, repeated across depression, addiction and end-of-life anxiety studies, suggests that psilocybin therapy works not primarily through pharmacological mechanisms but through the quality of the experience it reliably produces — which is precisely what the Mazatec tradition always understood.

Depression
Multiple randomized controlled trials — including a landmark 2021 trial in NEJM and a 2023 trial from Johns Hopkins — have shown significant and durable reductions in treatment-resistant depression following one to two psilocybin sessions with psychological support. Effect sizes are larger than those achieved by conventional antidepressants, and in some participants the effects appear to last months to years. The FDA granted psilocybin Breakthrough Therapy designation in 2018 for treatment-resistant depression and in 2019 for major depressive disorder.
End-of-Life Anxiety
Studies at Johns Hopkins and NYU in patients with life-threatening cancer diagnoses found that a single psilocybin session produced dramatic and lasting reductions in death anxiety, depression and existential distress — with approximately 80% of participants showing clinically significant improvement at six-month follow-up. Qualitatively, participants described a fundamental shift in their relationship to death itself rather than a reduction in fear. This is perhaps the research finding that maps most directly onto the indigenous ceremonial use of mushrooms in dying and transition.
Addiction
Studies on tobacco addiction (Johns Hopkins, 80% abstinence at six months — extraordinary by any measure for a notoriously treatment-resistant condition) and alcohol use disorder (NYU, significant reduction in drinking days) suggest that psilocybin may address addictive behavior through the same mechanism as its antidepressant effects: a fundamental shift in the subject's sense of self and their relationship to the craving.
The Default Mode Network
Neuroimaging research, primarily from Imperial College London, has shown that psilocybin dramatically reduces activity in the default mode network — the brain's "ego network," associated with self-referential thinking, rumination and the maintenance of the narrative self. This temporary dissolution of the self-model appears to create a period of increased neural flexibility — literally more connections between brain regions that don't normally communicate — which may underlie both the therapeutic effects and the sense of unity reported in mystical experiences.

What to Hold Carefully

The therapeutic results are real; the hype sometimes exceeds them. Psilocybin therapy is not a universal cure for depression, addiction or existential distress. The results are significant and replicated, but they are achieved in highly controlled settings, with extensive preparation and integration support, by carefully screened participants with trained guides. The experience of taking mushrooms at a festival or in a friend's living room without this framework produces entirely different results — and sometimes produces genuine harm.

The Mazatec tradition's critique of the contemporary psychedelic scene deserves to be heard. The warning that María Sabina's words contain is not that non-indigenous people cannot work with psilocybin — the clinical evidence demonstrates otherwise. It is that removing the medicine from its framework of intention, preparation, communal accountability and integration removes something essential from the process. The best therapeutic research implicitly acknowledges this: the most effective psilocybin therapy protocols are, structurally, variations of the dieta and ceremonial container that Mazatec tradition has maintained for centuries.

The law is behind the science. Psilocybin remains a Schedule I substance in most countries — including the United States federally, though Oregon, Colorado and several cities have moved toward decriminalization or regulated therapeutic access. The FDA approval process is ongoing. This legal status does not reflect the risk profile of psilocybin, which has among the lowest harm profiles of any psychoactive substance studied — but it does reflect the historical political context in which drug policy was made, which had nothing to do with pharmacology and everything to do with culture war.